SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Frida Kahlo

PatientFrida Kahlo
Date of birth1989-07-06
IdentifiersMRN HR-NI011-SYN; SSN (made up) 000-11-4390
Document date2026-10-29
AuthorMarisol Ortega, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review of function, mood, and the opioid taper. [S]

History of Present Illness

Ms. Kahlo returns six weeks after her first visit and two weeks after her oxycodone was reduced to 52.5 MME a day. She has had no yawning, gooseflesh, stomach cramps, diarrhea, restlessness, or loss of sleep beyond her usual. Her pain has not worsened, and her PEG is 5.3, 27 percent below the 7.3 she scored at intake. With the shoe lift she now stands at the easel for 25 to 30 minutes at a time. She goes to physical therapy twice a week and to cognitive behavioral therapy weekly, and she has had no falls. She takes acetaminophen 1 g three times a day. She asks when the next reduction will be and wants it to stay slow. [S]

ElementDetail
TaperTwo weeks at 52.5 MME a day; no withdrawal symptoms
PEG5.3, 27 percent below intake
FunctionStands 25 to 30 minutes at the easel with the shoe lift
RehabilitationPhysical therapy twice weekly; cognitive behavioral therapy weekly
SafetyNo falls; no sedation

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo sweats, chills, or sleep change
GastrointestinalNegativeNo stomach cramps, diarrhea, nausea, or constipation
MusculoskeletalPositiveBack, pelvic, and ankle pain, no worse since the reduction; no falls
NeurologicalPositiveBurning in the right leg, less than at intake; no new weakness; no bladder or bowel control change
PsychiatricNegativeMood steady; PHQ-9 score 4 with item 9 scored 0; no anxiety or restlessness

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Oxycodone 10 mg oral tablet, one tablet every 6 hours as needed for pain, no more than four a day (60 MME a day)One tablet by mouth every 6 hours as needed for pain; no more than 4 tablets a dayOral route2024-03-04 to 2026-10-15completedS
Oxycodone 10 mg oral tablet, one tablet three times daily as needed for painOne tablet by mouth three times daily as needed for painOral route2026-10-15activeS
Oxycodone 5 mg oral tablet, one tablet at bedtime as needed for painOne tablet by mouth at bedtime as needed for painOral route2026-10-15activeS
Duloxetine 30 mg delayed-release oral capsule, one capsule dailyOne capsule by mouth dailyOral route2026-09-17 to 2026-10-01completedS
Duloxetine 60 mg delayed-release oral capsule, one capsule dailyOne capsule by mouth dailyOral route2026-10-01activeS
Acetaminophen 500 mg oral tablet, two tablets three times dailyTwo tablets by mouth three times daily; no more than 3,000 mg a dayOral route2026-09-17activeS
Diclofenac sodium 1% topical gel, 2 g to the right ankle four times dailyApply 2 g to the right ankle and foot four times dailyTopical route2026-09-17activeS
Cholecalciferol (vitamin D3) 2,000 units oral tablet, one tablet dailyOne tablet by mouth dailyOral route2026-09-17activeS
Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose; may repeat in the other nostrilFor suspected opioid overdose: one spray into one nostril and call 911; if there is no response after 2 to 3 minutes, give a second spray in the other nostrilNasal route2026-09-17activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-29Body height160cmS
2026-10-29Body weight50.5kgS
2026-10-29Body mass index (BMI) [Ratio]19.7kg/m2S
2026-10-29Systolic blood pressure116mm[Hg]S
2026-10-29Diastolic blood pressure70mm[Hg]S
2026-10-29Heart rate76/minS
2026-10-29Respiratory rate14/minS
2026-10-29Body temperature36.6CelS
2026-10-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
2026-10-29Mean score [PEG]5.3{score}S
2026-10-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 2026-10-29; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and not sedated
EyesPupils equal, normal in size, and reactive; no tearing
SkinNo sweating or gooseflesh
BackLumbar paraspinal tenderness, less than at intake
Right ankleBony enlargement and reduced motion; no effusion
GaitCane and shoe lift; steady

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic low back and pelvic pain after remote spinal and pelvic fractures and spinal surgery, with neuropathic features in the right leg; linked to the documented 1925 injuriesactiveconfirmed G89.21S — Synthetic modern diagnosis linked to the documented injuries; the neuropathic interpretation is R.
Post-traumatic osteoarthritis of the right ankle and foot after multiple leg fractures and a foot dislocationactiveconfirmed M19.171S — Synthetic diagnosis confirmed on the synthetic ankle X-ray.
Right leg weakness, atrophy, and shortening after childhood poliomyelitis; a congenital spinal anomaly has been proposed retrospectivelyactiveprovisional B91S — Synthetic modern coding of the documented childhood diagnosis; the alternative remains R.
Long-term opioid therapy for chronic pain, 60 MME a day at intakeactiveconfirmed Z79.891S — Synthetic modern medication status; not a historical assertion.
Vitamin D deficiencyactiveconfirmed E55.9S — Synthetic finding from the baseline 25-hydroxyvitamin D.
Acute viral upper respiratory infection (common cold), resolved without antibioticsresolvedconfirmed J06.9S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPEG pain, enjoyment of life, and general activity scoreEvery visitCompleted today5.3, 27 percent below intake; the 30 percent goal continues
SurveyPHQ-9 depression score, with item 9Every 2 to 4 weeks during active treatmentCompleted today4, with item 9 scored 0
LaboratoryALT on regular acetaminophenPeriodically when acetaminophen approaches 3 g a dayCompleted today24 U/L, normal
Medication safetyOpioid withdrawal symptomsAt each contact after a reductionCompleted todayNone, here or at last week's visit
Medication safetyOpioid benefits and harms: function, sedation, constipation, fallsEvery visit during a taper; at least every 3 monthsCompleted todayFunction better; no sedation, constipation, or falls
Medication safetyTaper stepAbout 10 percent a month for long-term therapy, adjusted to her responseUp to dateNext step due in about two weeks
Medication safetyPrescription drug monitoring program checkBefore each opioid prescription; at least every 3 monthsUp to dateChecked at last week's visit: a single prescriber
LaboratoryUrine drug test, with consentBefore long-term therapy, then at least annuallyUp to dateAt intake; repeat within a year
Medication safetyOpioid use disorder assessmentBefore tapering and whenever concerns ariseUp to dateNo concerns since the assessment two weeks ago
Medication safetyNaloxone at home, with a family member trainedOffer when starting or continuing opioids; review each visitUp to dateAt home
Medication safetyConcurrent benzodiazepines or other sedativesEvery visitCompleted todayNone
ExaminationFall riskEvery visit while on opioids and duloxetineUp to dateTimed Up and Go 14 seconds last week; no falls
ExaminationRight ankle examination: range of motion, effusion, alignmentEvery visitCompleted todayUnchanged; no effusion
ImagingRight ankle radiographOnly for diagnostic uncertainty, clinical change, or surgical planningNot indicatedNo clinical change
LaboratoryCBC, creatinine, and blood pressure for chronic oral NSAID useEvery 6 to 12 months on oral NSAIDsNot indicatedTopical diclofenac only
Self-managementExercise and cognitive behavioral therapy adherenceEvery visitCompleted todayPhysical therapy twice weekly and cognitive behavioral therapy weekly
Laboratory25-hydroxyvitamin DAbout 3 months after starting repletionDueRecheck in about seven weeks

Goal progress:

Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians (2017); VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022); CMID: Clinical Monitoring Intelligence Database, osteoarthritis and depression monographs (2026)

Follow-up: Chronic pain review in two weeks for the second taper step. [S]